BioSpace News Archive

Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc., a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced its strategic, operational and financial results for the quarter ended September 30, 2022.

TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported financial results for the third quarter ended September 30, 2022, and recent business progress.

Instil Bio, Inc., a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, reported its third quarter 2022 financial results and provided a corporate update.

Harrow, an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, announced results for the third quarter ended September 30, 2022.

Movano Inc. dba Movano Health, a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, reported financial results for the three months ending September 30, 2022 and provided a business update.

Metacrine, Inc., a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, reported its third-quarter 2022 financial results.

Viracta Therapeutics, Inc., a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced that the Compensation Committee of Viracta’s Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 80,000 shares of common stock.

Vivani Medical, Inc. announced financial results for the third quarter ending September 30, 2022 and provides business updates.

DAXOR CORPORATION, the global leader in blood volume measurement technology, announced that it has commenced an underwritten public offering of shares of its common stock.

Biotheus Inc. announced that they have entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus’ EGFR/MET bispecific antibody in Greater China, including Mainland China, Hong Kong, Macao and Taiwan.